Results 231 to 240 of about 101,617 (297)

Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes

ACR Open Rheumatology, Volume 8, Issue 7, July 2026.
Objective Dipeptidyl peptidase‐4 inhibitors (DPP‐4i), glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are widely used for type 2 diabetes, yet their comparative immunologic safety is uncertain.
Arjun Mahajan, David W. Bates, Alessandro Doria, Dinah Foer, Avery H. LaChance, Jeffrey A. Sparks   +5 more
wiley   +1 more source

Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus.

J Clin Endocrinol Metab
Feng Y, Shang B, Yang Y, Zhang D, Liu C, Qin Z, Zhou Y, Meng J, Liu X.   +8 more
europepmc   +1 more source

Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Ahmed A, Tan Z, Abd El-Radi W, Rajamani K.   +3 more
europepmc   +1 more source

Microenvironmental Cues That Regulate Cancer Cell Dormancy in Estrogen‐Receptor Positive and Triple‐Negative Breast Cancer Cell Lines

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT The processes regulating cellular dormancy in tumor cells remain inadequately characterized. Further, there are very few models available that can recapitulate a dormancy‐like phenotype in vitro. In this study, we investigated the role of microenvironmental cues in inducing a dormancy‐like phenotype in estrogen receptor‐positive (MCF‐7) and ...
Jinesh Maniar, Pulkit Datt, Prerana P. Dange, Vaishali Kailaje, Mithlesh Lakhera, Mansi Samarth, Tanuja Durve, Anushree Kadam, Khushboo A. Gandhi, Sudeep Gupta   +9 more
wiley   +1 more source

Use of SGLT2 Inhibitors Versus DPP-4 Inhibitors and Age-Related Macular Degeneration in Patients WithType 2 Diabetes: A Multinational Cohort Study. [PDF]

Invest Ophthalmol Vis Sci
Pan SY, Weng CH, Tsai SF, Lin HJ, Lin JF, Lin CH, Wang IJ, Chou CC.   +7 more
europepmc   +1 more source

Hybrid Cell Membrane‐Coated NIR‐Photodegradable Carbon Nitride Nanozymes for Mangiferin Dual‐Targeted Delivery and Gas Mild Photothermal Immunotherapy Against Liver Fibrosis via the HIF‐1α/HSP27 Axis

Carbon Neutralization, Volume 5, Issue 4, July 2026.
We developed HMCCNs@MAN, a biomimetic drug–gas codelivery platform for precise mild photothermal immunotherapy of liver fibrosis. Coated with hybrid macrophage‐aHSC membranes, it enables dual‐targeted delivery of MAN to the hepatic fibrosis site. Under NIR laser irradiation, HMCCNs@MAN can generate oxygen, release MAN, and produce heat.
Ming‐Xuan Liu, Yue Yang, Xin‐Ru Zhao, Su‐Yun Zhang, Yu‐Ting Cai, Nan Zhang, Jue Wang, Ke‐Yang Xu, Zi‐Ming Zhao, Qi‐Biao Wu   +9 more
wiley   +1 more source

Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort study. [PDF]

EClinicalMedicine
Meng LC, Chuang HM, Lai HY, Chen HM, Yang KY, Chen LK, Hsiao FY.   +6 more
europepmc   +1 more source

Cardiovascular Outcomes With SGLT‐2 Inhibitors in Patients With Type 2 Diabetes and Obstructive Sleep Apnoea: A Real‐World Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7607-7610, August 2026.
Reuben L. Odai, Dennis Dela Tsagli, Anthony Alchaer, Laiba Sajjad, Kwame Adjei‐Sefah, Chukwuemeka Aghasili, Smith Frimpong, Hussam Farhoud   +7 more
wiley   +1 more source

Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Pirera E, Di Raimondo D, D'Anna L, Tuttolomondo A.   +3 more
europepmc   +1 more source